Expanding the molecular signatures of malignant ossifying fibromyxoid tumours with two novel gene fusions: PHF1::FOXR1 and PHF1::FOXR2

Ossifying fibromyxoid tumor (OFMT) is a rare enigmatic tumor of uncertain differentiation that can be classified as typical, atypical, and malignant subtypes based on cellularity, nuclear grade, and mitotic activity. The majority of OFMTs, regardless of the risk of malignancy, harbor genetic translocations. We report two malignant OFMTs, including one with evidence of dedifferentiation, with novel genefusions.

[1]  Henry W. Long,et al.  FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits , 2022, Cancer research.

[2]  D. Adams,et al.  FOXR1 regulates stress response pathways and is necessary for proper brain development , 2021, PLoS genetics.

[3]  I. John,et al.  Novel MEAF6‐SUZ12 fusion in ossifying fibromyxoid tumor with unusual features , 2021, Genes, chromosomes & cancer.

[4]  R. Veitia,et al.  Forkhead Transcription Factors in Health and Disease. , 2020, Trends in Genetics.

[5]  S. Wong,et al.  Superficial malignant ossifying fibromyxoid tumors harboring the rare and recently described ZC3H7B‐BCOR and PHF1‐TFE3 fusions , 2020, Journal of cutaneous pathology.

[6]  F. Mertens,et al.  PHF1 fusions cause distinct gene expression and chromatin accessibility profiles in ossifying fibromyxoid tumors and mesenchymal cells , 2020, Modern Pathology.

[7]  C. Antonescu,et al.  Novel recurrent PHF1‐TFE3 fusions in ossifying fibromyxoid tumors , 2019, Genes, chromosomes & cancer.

[8]  C. Antonescu,et al.  Expanding the molecular signature of ossifying fibromyxoid tumors with two novel gene fusions: CREBBP‐BCORL1 and KDM2A‐WWTR1 , 2017, Genes, chromosomes & cancer.

[9]  R. Geffers,et al.  Chromosome 11q23 aberrations activating FOXR1 in B-cell lymphoma , 2016, Blood Cancer Journal.

[10]  Roland Eils,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.

[11]  J. Goldblum,et al.  Ossifying fibromyxoid tumor: a clinicopathologic analysis of 26 subcutaneous tumors with emphasis on differential diagnosis and prognostic factors , 2015, Journal of cutaneous pathology.

[12]  Narasimhan P. Agaram,et al.  Novel ZC3H7B‐BCOR, MEAF6‐PHF1, and EPC1‐PHF1 fusions in ossifying fibromyxoid tumors—molecular characterization shows genetic overlap with endometrial stromal sarcoma , 2014, Genes, chromosomes & cancer.

[13]  O. Larsson,et al.  Recurrent rearrangement of the PHF1 gene in ossifying fibromyxoid tumors. , 2012, The American journal of pathology.

[14]  D. Gisselsson,et al.  Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma , 2012, Oncogene.

[15]  S. Raimondi,et al.  Ossifying Fibromyxoid Tumor of Soft Parts: A Clinicopathologic, Proteomic, and Genomic Study , 2011, The American journal of surgical pathology.

[16]  M. Miettinen,et al.  Ossifying Fibromyxoid Tumor of Soft Parts—A Clinicopathologic and Immunohistochemical Study of 104 Cases With Long-term Follow-up and a Critical Review of the Literature , 2008, The American journal of surgical pathology.

[17]  A. Folpe,et al.  Ossifying Fibromyxoid Tumor of Soft Parts: A Clinicopathologic Study of 70 Cases With Emphasis on Atypical and Malignant Variants , 2003, The American journal of surgical pathology.

[18]  H. Jäckle,et al.  The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo , 1989, Cell.